Trutakna (atacicept-vymj) is Vera Therapeutics' (NASDAQ: VERA) recombinant fusion protein combining the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1. The molecule binds both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage in primary IgA nephropathy.
The FDA granted accelerated approval to Trutakna on July 7, 2026 for adults with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Approval was based on Phase 3 ORIGIN trial data at 36 weeks: Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio compared with 6.8% for standard of care alone. Vera expects US launch in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.
The IgAN competitive set expanded July 17, 2026 when Novartis Fabhalta (iptacopan, a first-in-class complement Factor B small-molecule inhibitor) received FDA traditional approval for slowing kidney function decline in primary IgAN, based on Phase 3 APPLAUSE-IgAN data showing a 48% slower eGFR decline versus placebo. IgAN affects approximately 130,000-150,000 Americans and is the most common primary glomerular disease worldwide.
Stories here cover Trutakna trial readouts, commercial launch, and IgAN competitive positioning. See [[vera-therapeutics]], [[atacicept]], and [[iga-nephropathy]] for adjacent threads.
Boulevard Bio emerged from stealth on Wednesday August 12, 2026 with $65 million in founding financing from Deerfield Management, naming Georg Schett (one of the pioneers of immune reset in autoimmune disease) as co-founder. The company disclosed a precision-immunology pipeline of three drug candidates anchored by BLVD101, an internally discovered dual BAFF/APRIL-targeting bispecific antibody. Mechanism: BLVD101 is designed to inhibit BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand), two cytokines that promote the proliferation, survival, and maturation of B cells that drive autoimmune disorders. By blocking both cytokines simultaneously, BLVD101 aims to limit the abnormal B cell activity that attacks healthy tissue in autoimmune diseases. Early Phase 1 healthy volunteer data supports a 12-week (quarterly) subcutaneous dosing interval for BLVD101 in IgA nephropathy (IgAN), a positive tolerability and pharmacokinetic profile that would compare favorably against monthly-dosing biologics in adjacent indications. The launch extends the IgAN indication activity that Trutakna and Fabhalta opened up earlier in 2026 with their FDA approvals ten days apart in the same indication category, though those two drugs target the complement pathway (factor B, C5) rather than the B-cell BAFF/APRIL axis that BLVD101 addresses.
July 2026 closed as the most consequential peptide-and-obesity policy month in the site's coverage window. Regulatory milestones: the July 1 Medicare GLP-1 Bridge Program launch providing Wegovy (semaglutide), Zepbound KwikPen (tirzepatide), and Foundayo (orforglipron) at $50/month capped copay for approximately 3.8 million eligible Medicare Part D beneficiaries through December 31, 2027; the July 23-24 FDA Pharmacy Compounding Advisory Committee (PCAC) two-day session recommending 6 of 7 research peptides for the Section 503A Bulks List (BPC-157 8-6-1, KPV 8-6-1, TB-500 8-6, MOTS-c 7-5-2, Semax 8-5, Epitalon 7-4; Emideltide/DSIP rejected); the July 30 close of the 503B GLP-1 Bulks List exclusion comment period on the April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide; and the Section 232 pharmaceutical tariffs effective date July 31. Product milestones: the July 16 FDA approval of Merck LIPFENDRA (enlicitide) as the first once-daily oral macrocyclic peptide PCSK9 inhibitor (56-59% LDL reduction in CORALreef Phase 3, $315/month launch pricing); the July 7 FDA accelerated approval of Vera Therapeutics TRUTAKNA (atacicept-vymj) for primary IgA nephropathy; the July 17 FDA traditional approval of Novartis Fabhalta (iptacopan) for IgAN; the July 23 Arrowhead Redemplo (plozasiran) Phase 3 SHASTA-3 and SHASTA-4 positive readout (79-81% triglyceride reduction). Industry milestones: the July 19-20 Samsung Biologics $1.8 billion all-cash tender offer for PolyPeptide; the July 21 Novo Nordisk lawsuit and July 24 TRO filing against Eli Lilly over GLP-1 advertising; the July 20-23 EMA CHMP recommendation for lerodalcibep (Lyrokaul) monthly PCSK9 fusion protein.
Vera Therapeutics (NASDAQ: VERA) confirmed commercial-launch parameters for TRUTAKNA (atacicept-vymj) following the July 7, 2026 FDA accelerated approval for adults with primary IgA nephropathy at risk of rapid disease progression. List price: $425,000 per year for the recombinant peptide-and-Fc fusion protein (TACI extracellular domain fused to human IgG1 Fc). Sales force: 82 representatives deployed at launch. Distribution: in-channel pharmacy availability within three to four weeks of approval, with insurance coverage under specialty-pharmacy medical benefit pathways given the subcutaneous injection administration. The July 7 accelerated approval was based on the Phase 3 ORIGIN study 36-week urine protein-to-creatinine ratio (UPCR) endpoint (45.7% reduction versus 6.8% for standard of care). Continued FDA approval may be contingent on verification of clinical benefit in the ongoing ORIGIN 3 confirmatory trial, which continues in a placebo-controlled blinded manner to evaluate change in kidney function as measured by estimated glomerular filtration rate (eGFR); results are anticipated in Q3 2026. If the ORIGIN 3 eGFR data hit, TRUTAKNA converts to traditional approval on the harder outcome endpoint.
Novartis (SIX: NOVN) announced Friday July 17, 2026 that the FDA has granted traditional approval for Fabhalta (iptacopan) to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of disease progression. Fabhalta is a first-in-class complement Factor B inhibitor (small molecule); the traditional approval converts the August 2024 FDA accelerated approval (which was based on proteinuria reduction) into a full label supported by kidney-function outcomes. The Phase 3 APPLAUSE-IgAN trial showed a 3.02 mL/min/1.73 m² per year difference in estimated glomerular filtration rate (eGFR) slope in the iptacopan arm versus placebo, translating to a 48% slower kidney-function decline. The approval extends the primary IgA nephropathy competitive set that Vera Therapeutics entered on July 7, 2026 when Trutakna (atacicept-vymj), a BAFF/APRIL-targeting peptide-and-Fc fusion protein, received FDA accelerated approval based on a 45.7% versus 6.8% reduction in urine protein-to-creatinine ratio in the Phase 3 ORIGIN trial. IgA nephropathy affects approximately 130,000-150,000 Americans and is the most common primary glomerular disease worldwide; roughly 40% of patients progress to end-stage renal disease within 20 years without effective treatment.
Endpoints News published a mid-year FDA review Wednesday reporting that the FDA cleared 23 novel drugs through June 30, 2026, the best first half of a year for novel approvals since 2023. The pace held up despite the Trump administration's April 2025 FDA staff cuts that industry observers had feared would slow the approval machine. Total regulatory verdicts in H1 2026 ran 79 (slight decrease from 85 in H1 2025), but novel approvals ticked up substantially from 19 in H1 2025 to 26 by the Endpoints tally (approaches vary slightly by definition; the FDA's Novel Drug Approvals for 2026 tracker shows 23 through the June 30 cutoff). Approvals during the period spanned oncology, infectious disease, nephrology, dermatology, ophthalmology, and metabolic disease. The peptide-relevant approvals within this pace include Yuviwel (navepegritide, Ascendis Pharma's once-weekly C-type natriuretic peptide prodrug for pediatric achondroplasia; accelerated approval February 27), Foundayo (orforglipron, Eli Lilly's oral small-molecule GLP-1 for chronic weight management; April 1), Tryngolza (olezarsen, Ionis's ASO for severe hypertriglyceridemia; June 24), and Trutakna (atacicept, Vera Therapeutics' BAFF/APRIL fusion protein for IgA nephropathy; July 7). The staff-cut concern has partially receded, though longer-term impacts on Center for Drug Evaluation and Research (CDER) throughput remain a Q3-Q4 2026 story to watch.
The FDA granted accelerated approval Tuesday July 7, 2026 to Trutakna (atacicept-vymj) for adult patients with primary IgA nephropathy (IgAN) at risk of rapid disease progression, in combination with standard of care. Vera Therapeutics developed the drug as a recombinant fusion protein that combines the extracellular domain of the transmembrane activator and CAML interactor (TACI) receptor with the Fc portion of human IgG1, binding both B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL) to reduce autoantibody-driven kidney damage. The registrational Phase 3 ORIGIN trial data supporting approval: at 36 weeks, Trutakna plus standard of care produced a 45.7% reduction in urine protein-to-creatinine ratio versus a 6.8% reduction for standard of care alone. IgA nephropathy affects approximately 130,000 to 150,000 Americans and is the most common primary glomerular disease worldwide; approximately 40% of patients progress to end-stage renal disease within 20 years without adequate treatment. Trutakna is a fusion protein rather than a peptide but sits in adjacent therapeutic territory relevant to the site's peptide-and-biologic coverage. Vera Therapeutics (NASDAQ: VERA) is expected to launch the product in Q3 2026. Continued approval may be contingent on verification of clinical benefit in confirmatory Phase 3 studies.